阿莫西林与莫西沙星治疗幽门螺旋杆菌胃病的临床疗效及药理学分析

Clinical Efficacy and Pharmacological Analysis of Amoxicillin and Moxifloxacin in the Treatment of Helicobacter Pylori Stomach Disease

目的研究在幽门螺旋杆菌胃病治疗中采用莫西沙星与阿莫西林的效果。方法样本方便选自该院2017年3月—2018年3月收治的180例幽门螺旋杆菌胃病患者,按照随机的原则将患者分为对照组与观察组,每组患者90例,对照组患者为阿莫西林患者,观察组患者为采用莫西沙星治疗患者,比较两组患者缓解率、不良反应发生率、预后生活质量。结果观察组90例患者总缓解率为93.3%,对照组90例患者总缓解率为64.4%;观察组患者不良反应发生率为3.3%;对照组患者发生率为21.1%,不良反应发生情况差异显著,其中观察组患者治疗后较为优异(χ~2=6.5312,P<0.05)。结论在幽门螺旋杆菌胃病患者治疗中采用莫西沙星治疗,可有效改善患者不良反应发生情况。

Objective To study the effects of moxifloxacin and amoxicillin in the treatment of Helicobacter pylori.Methods The samples were convenient selected from 180 patients with Helicobacter pylori stomach disease admitted from March 2017 to March 2018 in our hospital.The patients were divided into control group and observation group according to the principle of randomness.90 patients in each,the control group was treated with moxilin,the patients in the observation group were treated with moxifloxacin,and the remission rate,adverse reaction rate,and prognosis quality of life were compared between the two groups.Results The total remission rate was 93.3%in 90 patients in the observation group,64.4%in 90 patients in the control group,3.3%in the observation group,and 21.1%in the control group.Significantly,the patients in the observation group were superior after treatment(χ^2=6.531 2,P<0.05).Conclusion Moxifloxacin treatment in patients with Helicobacter pylori stomach disease can effectively improve the occurrence of adverse reactions in patients.